Explore our verified ODM pipeline designed for global pharmaceutical manufacturers, nutricosmetic innovators, and dietary supplement enterprises demanding reproducible bioactivity.
Phytochemistry of medicinal plants has evolved from traditional observational extraction into multi-target molecular medicine. Modern drug registration, botanical dietary supplements, and cosmeceutical actives require rigid batch-to-batch chemical equivalence.
Botanical therapeutics derive efficacy from synergistic matrices of alkaloids, polyphenols, flavonoids, and terpenoids. ODM manufacturers must identify whether targeted biological outcomes stem from isolated single chemical entities or holistic multi-component entourage mechanisms.
International pharmacopeias (USP, Ph. Eur., ChP) now penalize single-marker assays vulnerable to synthetic adulteration. High-performance liquid chromatography (HPLC) paired with thin-layer chromatography (HPTLC) is compulsory to preserve authentic chemical fingerprints.
Industrial scalability necessitates a move away from chlorinated solvents toward Supercritical CO2 (scCO2), continuous countercurrent extraction, and macroporous resin adsorption, cutting carbon footprints while maximizing active biomarker yields.
MedGence (Yineng Pharma) converts botanical complexity into pharmaceutical rigor across 14+ years of dedicated phytochemical research and high-capacity contract manufacturing.
From single-compound target screening to cGMP commercial validation, our engineering teams remove blind spots across the entire phytochemical product lifecycle.
High-throughput affinity selection targeting receptor ligands, enzyme inhibitors, and antioxidants. We screen diverse botanical libraries to uncover molecules with superior bioavailability and therapeutic indexes.
Microclimates, soil chemistry, and phenological harvesting windows alter active marker concentrations. We evaluate regional chemotypes across seasons to guarantee maximum baseline yield.
Establishing robust ICH Q2(R1) validated analytical assays: HPLC, GC-MS, LC-MS/MS, and high-performance thin-layer chromatography fingerprints to detect and quantify target biomarkers and impurities.
Comprehensive toxicity profiles: GLP-compliant in vitro cytotoxicity, acute oral toxicity (LD50), sub-chronic 90-day studies, Ames genotoxicity, and in vivo animal disease models to substantiate safety margins.
Human clinical trial execution: Double-blind, placebo-controlled clinical protocols to prove efficacy for functional health claims, nutraceutical applications, or botanical New Drug Applications (NDA).
Direct pilot-to-commercial scale transition. Formulation stability optimization into oral liquids, botanical softgels, two-piece hard capsules, compressed tablets, and standardized extract powders.
International trade in botanical derivatives requires absolute compliance with jurisdictional contaminants, residue barriers, and novelty thresholds.
Full qualification for 21 CFR Part 111 (Dietary Supplements) and Part 211 (cGMP Pharma). Complete documentation packages supporting New Dietary Ingredient Notifications (NDIN) and GRAS dossiers.
Aligning with European Herbal Compendium monographs, Traditional Herbal Medicinal Products Directive (THMPD), strict Polycyclic Aromatic Hydrocarbons (PAH4) limits, and pesticide residue controls.
Validated ICP-MS testing for heavy metals (Lead, Arsenic, Cadmium, Mercury), LC-MS/MS analysis for 500+ multi-residue pesticides, and testing for aflatoxins, pyrrolizidine alkaloids, and microbials.
Seamless support for China NMPA Hospital Preparations and Class 1.1/2.3 botanical innovation drugs, anchored by our 56 hospital preparation approvals and proprietary herbal databases.
Delivering tailored chemical profiles matched directly to client stability criteria, bio-absorption requirements, and sensory expectations.
Standardized berberine analogs, mulberry leaf DNJ fractions, and polyphenol-rich matrices engineered for alpha-glucosidase inhibition, stabilized in delayed-release oral forms.
High-purity bacosides, ginsenoside monomer extracts (Rg1, Rb1, Rd), and gastrodin fractions formulated for blood-brain barrier permeability and enhanced neuro-receptor affinity.
Purified madecassoside, glabridin, and resveratrol fractions optimized through nano-emulsification and liposomal delivery to overcome dermal stratum corneum transport limitations.
How MedGence is integrating synthetic biology, artificial intelligence, and continuous molecular profiling into modern botanical medicine manufacturing.
Deploying deep machine-learning algorithms to model molecular target interactions, simulate in silico binding affinities, and predict off-target toxicity before conducting wet-lab clinical assays.
Overcoming agricultural yield constraints for rare phytochemicals by leveraging microbial chassis and directed enzyme biotransformation for ultra-rare ginsenosides and specific triterpenes.
Integrating Process Analytical Technology (PAT) using Near-Infrared (NIR) spectroscopy within industrial extraction columns, enabling continuous process tuning without batch hold-times.
Over 100 enterprise partners trust MedGence for reproducible phytochemical testing, contract formulation, and clinical regulatory documentation.
China Beijing Tongrentang Group
CR Sanjiu Medical & Pharmaceutical
Sunflower Pharmaceutical Group
Livzon Pharmaceutical Group
Dihon Pharmaceutical Group
Yangtzi River Pharmaceutical
Humanwell Healthcare Group
Shuguang Hospital, Shanghai TCM
Essential technical and regulatory insights for procurement directors, principal investigators, and global supply managers.
Engage our laboratories for custom synthesis, analytical standardization, or complete turn-key CDMO commercial batch supply.
